Apogee Therapeutics Inc APGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $58.04
- Day Range
- $57.40–59.06
- 52-Week Range
- $14.19–72.29
- Bid/Ask
- $57.99 / $58.02
- Market Cap
- $3.29 Bil
- Volume/Avg
- 266,343 / 444,504
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 91
Comparables
Valuation
|
Metric
|
APGE
|
EXEL
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.02 | 39.71 |
Price/Book Value | 4.25 | 3.49 | 20.78 |
Price/Sales | — | 3.97 | 10.36 |
Price/Cash Flow | — | 16.25 | 27.07 |
Price/Earnings
APGE
EXEL
TGTX
Financial Strength
|
Metric
|
APGE
|
EXEL
|
TGTX
|
|---|---|---|---|
Quick Ratio | 27.47 | 4.05 | 2.77 |
Current Ratio | 27.70 | 4.27 | 3.58 |
Interest Coverage | — | — | 8.72 |
Quick Ratio
APGE
EXEL
TGTX
Profitability
|
Metric
|
APGE
|
EXEL
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −20.30% | 14.82% | 40.17% |
Return on Equity (Normalized) | −19.63% | 19.05% | 94.57% |
Return on Invested Capital (Normalized) | −26.19% | 14.99% | 57.84% |
Return on Assets
APGE
EXEL
TGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ffdknpbxq | Hbnt | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dfvwhtqh | Bzgcsw | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rxdrhdms | Cnmwj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yrlgncf | Khwgk | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Htqjwvfws | Cdjl | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Krkmdmky | Bnkw | $28.1 Bil | |||
| Moderna Inc
MRNA
| Tfyvkhh | Fwkpv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dyvcylg | Vzw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nyqwdckt | Wfwvf | $13.4 Bil | |||
| Incyte Corp
INCY
| Pwjhgtrwd | Yvxjgn | $12.7 Bil |
United States